NEW YORK, March 1 - Proteome Systems said Thursday it had reached an agreement with Kratos Analytical to jointly develop software that would help to further automate Kratos’ AXIMA family of mass spectrometers.
Financial terms were not disclosed.
The deal follows on the heels of a December announcement that Proteome and Kratos’ parent company Shimadzu Biotech would jointly establish proteomics facilities in Sydney, Australia, and Boston. That deal was also an extension of a previous agreement.
The latest announcement is designed to address many of the current bottlenecks in high throughput automation for MALDI applications in proteomics.
The two companies said they would work together to develop software to process information as part of a plan to integrate Proteome Systems sample preparation technologies with the Xcise and Chemical Printer, which was jointly developed by Proteome Systems and Shimadzu, and Kratos’ MALDI-TOF mass spectrometers.
"We are excited to be moving from technology development to high throughput discovery programs based on the combination of Proteome Systems' new instrumentation and the new generation Kratos MALDI mass spectrometers,” Keith Williams, CEO of Proteome Systems, said in a statement. “The final link in this chain is information processing and we are delighted to expand our relationship with Kratos (and Shimadzu) to include this area."
Based in Sydney and Boston, Proteome Systems, develops its own instruments, consumables, and informatics technologies and partners with leading technology companies for the development of proteomics technologies.
Kratos Analytical, of Manchester, UK, is a wholly-owned subsidiary of Japan’s Shimadzu Corporation. Kratos manufactures MALDI-TOF mass spectrometers.
Shimadzu and Proteome Systems have said that they expect to launch their first jointly developed system around August 2001.
Neither company was immediately available for comment.